Title: Study: Aspirin cuts colorectal cancer recurrence in half
Article Snip: "...The study included more than 3,500 patients with colon and rectal cancer from dozens of hospitals in Sweden, Norway, Denmark and Finland. Patients whose tumors showed a specific genetic mutation in the PIK3CA signaling pathway. The mutation, according to Medical Xpress, was found in approximately 40% of patients. Those patients were randomly chosen to receive either 160 mg of aspirin daily or a placebo for three years after surgery. ...For patients with the genetic mutation in PIK3, the risk of recurrence was reduced by 55% in those who received aspirin compared with the placebo group."
Reference: www.newsnationnow.com